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Clinical trials and biostatistics workshop: introduction and 
overview
Crowley, John 
Cancer Research And Biostatistics, Seattle, WA, USA
This unique workshop was designed to bring together clinicians and 
statisticians to discuss current problems and potential solutions to issues 
in the design and analysis of lung cancer clinical trials and translational 
science. Each of the afternoon sessions pairs an oncologist with a bio-
statistician (some also have a formal discussant) to present a particular 
issue and approach. Two evening panels explore opportunities for lung 
cancer trials in Asia, and different models for clinical trial conduct.
Many of the current issues arise because of the development of newer, 
targeted therapies. The traditional phase II endpoint of tumor shrinkage 
may no longer be appropriate in such settings, and there may not be 
good historical data on newer endpoints such as disease control rate, 
so new phase II and phase II/III designs are needed. In addition, the 
degree to which therapies are targeted (and targets can be measured) 
has implications for the design of phase III trials. 
The ability to measure thousands of gene expression levels, gene vari-
ants or gene products brings with it the challenge of sorting through 
these high dimensional data sets to identify which patients will beneﬁt 
from particular therapies. The goal is to use genetic characteristics of 
the tumor and/or the host to tailor therapy.
Finally, the hope persists that the patient’s immune system can be 
enhanced and used to ﬁght cancer. This ﬁeld of immunotherapy also 
raises particular issues of clinical trial design.
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Phase II Trials - endpoints, when to randomize
Zee, Benny 
Department of Clinical Oncology, The Chinese University of Hong 
Kong, Hong Kong, China
The primary objective of phase II trials is to screen a new agent or regi-
men for efﬁcacy and to provide estimates of its level of activity. In this 
workshop we will discuss commonly used endpoints such as complete 
plus partial response rate (overall response rate) and their correspond-
ing analysis and interpretation. The use of multiple-stage design to 
minimize increase the efﬁciency of screening will be discussed. The 
importance in the design of phase II trials to minimize the chance that a 
truly active agent is erroneously rejected will also be discussed. There 
are circumstances that randomized phase II trial may be appropriate 
and its correct interpretation will be discussed. 
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Designs with targeted therapies
West, Howard 
Swedish Cancer Institute, Seattle, WA, USA
The study of targeted therapies in oncology requires consideration 
of several features that are unique to this class of agents. Trials of 
molecularly targeted therapies need to carefully assess whether it is 
appropriate to restrict the study of a targeted therapy to a population 
with a molecular variable that may be particularly relevant to a targeted 
therapy, or whether it is more appropriate to open the trial to a broader 
population that may experience a less consistent and robust improve-
ment in clinical endpoints. Designs of trials with targeted therapies may 
also need to redeﬁne the importance of such endpoints as maximum 
tolerated dose versus minimal effective dose, and of objective response 
versus disease control/non-progression. Trials designed as a “window 
of opportunity” allow for the rapid testing of a targeted therapy with a 
biological endpoint, while other trials with this design may incorporate 
novel endpoints such as metabolic imaging to assess results rapidly. 
Examples of clinical trials with targeted therapies in lung cancer also 
illustrate how early use of combinations of conventional chemotherapy 
and targeted therapy may obfuscate the contribution of the molecular 
therapy or may even produce antagonistic combinations, and of how a 
cross-over design may introduce new challenges in the interpretation 
of the contribution of a novel targeted therapy. Finally, multi-targeted 
single agents and combinations of different targeted therapies raise 
additional questions in clinical trial design of how to optimize efﬁcacy, 
minimize safety risks, and evaluate the clinical beneﬁt of regimens 
compared with traditional standards using more conventional agents.
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Novel clinical trial design applying Bayesian adaptive 
randomization for targeted therapy in lung cancer - A step toward 
personalized medicine
Lee, J. Jack 
Department of Biostatistics, M. D. Anderson Cancer Center, Houston, 
TX, USA
Background: With the advancement in the understanding of multiple 
signaling pathways associated with lung cancer, many targeted thera-
pies have been developed. Utilization of molecularly targeted agents 
can inhibit these speciﬁc aberrant pathways, hence, lead to clinical 
efﬁcacy. The targeted agents, however, may not work for everyone. 
Biomarkers expressions can be used as indicators for the aberrant 
signaling to identify effective targeted therapy. Our major goals are to 
characterize the molecular signature of individual tumors, to offer best-
ﬁt targeted therapy to patients on the trial, and to identify promising 
targeted agents for future development. 
Methods: We have developed the “BATTLE” program, “Biomarker-
integrated Approaches of Targeted Therapy of Lung Cancer Elimina-
tion,” which consists of an umbrella screening trial and 4 parallel phase 
II targeted therapies trials (with erlotinib, sorafenib, vandetanib, and 
the combination of erlotinib and bexarotene) in advanced non-small 
cell lung cancer patients with prior chemotherapy. All patients will 
have biopsy samples taken for biomarker proﬁle assessment prior to 
the randomization, then they will be classiﬁed into one of the ﬁve 
marker groups: 1) EGFR mutation/ampliﬁcation, 2) K-ras and/or B-raf 
mutation, 3) VEGF and/or VEGFR expression, 4) RXR and/or cyclin 
